Bojana Turic, MD – Director, President & CEO

As CEO of PMI Labs, Dr. Turic's extensive experience andproven ability to lead will be instrumental in the expansion of service and continued commercialization of innovative technology for early cancer detection products. Prior to being appointed CEO, Dr. Turic served as Vice President and COO. As one of the senior scientists of PMI Labs when it was founded in 1999, she has led the Company through significant clinical and regulatory milestones including, positioning the company as a world leader in early cancer diagnostic technologies, the development of strategic commercialization alliances, and execution of the company’s first commercial agreements. Dr. Turic completed her MD at the University of Sarajevo, Bosnia and Herzegovina where she held the position of Assistant Professor of Medical Microbiology.

Darren Zilinsky, BComm, CMA – Chief Financial Officer

Mr. Zilinsky worked from 2001 until 2005 at Vigil Health Solutions Inc. (CDNX: VGL.V), a software company specializing in services for the long-term health care market. There he spanned roles from Accounting Analyst to Controller and played an integral part in structuring and managing financial programs such as a limited partnership, various private placements and helped the company with their reverse takeover on the TSX Venture exchange in 2002. In 2005, Mr. Zilinsky joined WEX Pharmaceuticals Inc. (Toronto: WXI.TO) as Corporate Controller and was responsible for all financial reporting, budgeting and compliance issues. During his time with WEX, Mr. Zilinsky implemented a controlled budget system, improved corporate governance compliance and helped to streamline quarterly and annual external audits.

Mr. Zilinsky has been with PMI since 2006 and served as CFO since 2008.

Mr. Zilinsky holds a CMA designation and a Commerce degree in International Business from the University of Victoria.

Alexei Doudkine, PhD – Clinical & Business Development

Alexei Doudkine, Ph.D. is a Director of Business Development at Perceptronix, focusing on new business opportunities, partnerships and collaborations. Previously Dr. Doudkine served as Director of Quantitative Pathology Products, managing development of company’s automated image cytometry devices and quantitative cytology services. Dr. Doudkine has over 20 years of experience in medical device industry developing novel imaging and spectroscopy technology for various biomedical applications. He is an author or co-author of more than 20 papers and co-inventor in several patents on application of digital imaging technology to early detection of cancer. Dr. Doudkine holds PhD in Computer Science from St. Petersburg Electrical Engineering University (Russia) and MSc in Applied Mathematics from St. Petersburg State University.